<p>隨着全球市場在消費者通脹上升和企業盈利強勁的背景下航行，像標準普爾 500 指數和納斯達克綜合指數這樣的指數達到了新高，反映了投資者的樂觀情緒。在這種背景下，內部持股比例高的成長型公司尤其引人注目；它們在創新潛力和內部人士與股東之間的利益一致性方面可以為當今市場環境提供獨特的機會。</p>
<h3>全球內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>浙江零跑科技 (SEHK:9863)</td>
<td>15.6%</td>
<td>61%</td>
</tr>
<tr>
<td>上海華測導航技術 (SZSE:300627)</td>
<td>24.3%</td>
<td>23.5%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>M31 科技 (TPEX:6643)</td>
<td>30.8%</td>
<td>63.4%</td>
</tr>
<tr>
<td>老普金 (SEHK:6181)</td>
<td>35.5%</td>
<td>42.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>94.5%</td>
</tr>
<tr>
<td>金電路電子 (TWSE:2368)</td>
<td>31.4%</td>
<td>25.9%</td>
</tr>
<tr>
<td>富林精密 (SZSE:300432)</td>
<td>13.6%</td>
<td>43.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>79%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們快速增長的全球內部持股比例高的 813 只股票的完整列表。</p>
<p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
<h2>潤本股份 (SHSE:603193)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 潤本股份有限公司專注於蚊蟲驅避產品、嬰兒護理產品和精油產品的研究、生產和銷售，市值為 119.9 億人民幣。</p>
<p><strong>運營：</strong> 公司的收入主要來自個人護理產品部門，總計為 13.9 億人民幣。</p>
<p><strong>內部持股比例：</strong> 29.2%</p>
<p><strong>收入增長預測：</strong> 年均 24.2%。</p>
<p>潤本股份的收入增長強勁，預計年均增長 24.2%，超過中國市場平均水平。儘管市盈率高達 42.7 倍，但仍低於行業平均水平。預計未來三年盈利將顯著增長，年均增長 24.33%，超出市場預期。最近的第一季度業績顯示強勁表現，銷售額達到 2.4003 億人民幣，淨收入從去年的 4420 萬人民幣增加至 4420 萬人民幣。</p>
<ul>
<li>點擊這裏瞭解潤本股份的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們的潤本股份估值報告中的分析暗示其股價相較於估計價值被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/41571584-04fe-437d-8261-8c6c369a4bae/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/41571584-04fe-437d-8261-8c6c369a4bae/chart/ownership-breakdown"/></p>
<p>截至 2025 年 7 月的 SHSE:603193 持股結構</p>
<h2>上海華測導航技術 (SZSE:300627)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 上海華測導航技術有限公司在導航技術領域運營，市值為 277 億人民幣。</p>
<p><strong>運營：</strong> 上海華測導航技術有限公司的收入來自其導航技術領域的運營。</p>
<p><strong>內部持股比例：</strong> 24.3%</p>
<p><strong>收入增長預測：</strong> 年均 24.5%。</p>
<p>上海華測導航技術有望實現顯著增長，預計未來三年盈利將年均增長 23.5%，超過中國市場。收入也預計年均增長 24.5%，超出市場平均水平。公司最近的第一季度業績顯示強勁表現，銷售額上升至 7.8912 億人民幣，淨收入達到 1.4274 億人民幣，反映出強勁的運營勢頭，儘管市盈率低於行業平均水平，為 44.8 倍。</p>
<ul>
<li>點擊這裏訪問我們的完整增長分析報告，以瞭解上海華測導航技術的動態。</li>
<li>我們精心準備的上海華測導航技術估值報告暗示其股價可能過高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dfee584a-1911-4802-88a1-e9a681c151fe/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dfee584a-1911-4802-88a1-e9a681c151fe/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 7 月的 SZSE:300627 盈利和收入增長</p>
<h2>ASE 科技控股 (TWSE:3711)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> ASE 科技控股有限公司及其子公司提供半導體制造服務，包括組裝和測試，覆蓋美國、台灣、歐洲、亞洲及全球，市值約為 6562.5 億新台幣。</p>
<p><strong>運營：</strong> 公司的收入部門包括測試 58.94 億新台幣、包裝 276.77 億新台幣和電子組裝部門 310.28 億新台幣。</p>
<p><strong>內部持股比例：</strong> 28.5%</p>
<p><strong>收入增長預測：</strong> 年均 10.9%。</p>
<p>ASE 科技控股顯示出增長潛力，預計未來三年盈利將年均增長 24.9%，超過台灣市場。最近的收入數據顯示出積極趨勢，第二季度淨收入達到 1507.5 億新台幣，較去年 1402.4 億新台幣有所增長。然而，其 3.45% 的股息收益率未能很好地覆蓋自由現金流，且股票交易價格顯著低於估計的公允價值，儘管預計的股本回報率較低，僅為 16.1%。</p>
<ul>
<li>在我們的盈利增長報告中更深入地瞭解 ASE 科技控股的潛力。</li>
<li>我們精心準備的 ASE 科技控股估值報告暗示其股價可能低於預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5e85c188-9c9b-4f8e-8f7f-6f7a9a1226f0/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5e85c188-9c9b-4f8e-8f7f-6f7a9a1226f0/chart/ownership-breakdown"/></p>
<p>截至 2025 年 7 月的 TWSE:3711 持股結構</p>
<h2>將想法轉化為行動</h2>
<ul>
<li>點擊這裏深入瞭解 813 家快速增長的全球內部持股比例高的公司的宇宙。</li>
<li>尋找新視角？人工智能即將改變醫療保健。這 26 只股票正在從早期診斷到藥物發現等各個方面進行工作。最重要的是——它們的市值都在 100 億美元以下——仍然有機會提前佈局。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖作為財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

潤本股份

零跑汽車

<p>隨着全球市場面臨消費者通脹上升和強勁的企業盈利，標普 500 指數和納斯達克綜合指數已達到新高。內部持股比例高的成長型公司因其創新潛力和利益一致性而備受關注。前十家公司包括浙江零跑科技、上海華測導航技術和潤本股份，均顯示出良好的收入增長預測。然而，一些公司，如 ASE Technology Holding，面臨股息覆蓋和股票估值的挑戰。本分析突顯了當前市場環境中的機會</p>

<p>As global markets navigate a landscape of rising consumer inflation and robust corporate earnings, indices like the S&amp;P 500 and Nasdaq Composite have reached new highs, reflecting investor optimism. Amidst this backdrop, growth companies with high insider ownership are particularly intriguing; their potential for innovation and alignment of interests between insiders and shareholders can offer unique opportunities in today's market environment.</p>
<div class="lb-trans"><p>隨着全球市場在消費者通脹上升和企業盈利強勁的背景下航行，像標準普爾 500 指數和納斯達克綜合指數這樣的指數達到了新高，反映了投資者的樂觀情緒。在這種背景下，內部持股比例高的成長型公司尤其引人注目；它們在創新潛力和內部人士與股東之間的利益一致性方面可以為當今市場環境提供獨特的機會。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Zhejiang Leapmotor Technology (SEHK:9863)</td>
<td>15.6%</td>
<td>61%</td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology (SZSE:300627)</td>
<td>24.3%</td>
<td>23.5%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>M31 Technology (TPEX:6643)</td>
<td>30.8%</td>
<td>63.4%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>42.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>94.5%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>25.9%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>13.6%</td>
<td>43.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>79%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>浙江零跑科技 (SEHK:9863)</td>
<td>15.6%</td>
<td>61%</td>
</tr>
<tr>
<td>上海華測導航技術 (SZSE:300627)</td>
<td>24.3%</td>
<td>23.5%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>M31 科技 (TPEX:6643)</td>
<td>30.8%</td>
<td>63.4%</td>
</tr>
<tr>
<td>老普金 (SEHK:6181)</td>
<td>35.5%</td>
<td>42.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>94.5%</td>
</tr>
<tr>
<td>金電路電子 (TWSE:2368)</td>
<td>31.4%</td>
<td>25.9%</td>
</tr>
<tr>
<td>富林精密 (SZSE:300432)</td>
<td>13.6%</td>
<td>43.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>79%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 813 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們快速增長的全球內部持股比例高的 813 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
</div><h2>Runben Biotechnology (SHSE:603193)</h2>
<div class="lb-trans"><h2>潤本股份 (SHSE:603193)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Runben Biotechnology Co., Ltd. focuses on the research, production, and sale of mosquito repellent products, baby care products, and essential oil products, with a market cap of CN¥11.99 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 潤本股份有限公司專注於蚊蟲驅避產品、嬰兒護理產品和精油產品的研究、生產和銷售，市值為 119.9 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its personal products segment, totaling CN¥1.39 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自個人護理產品部門，總計為 13.9 億人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 29.2%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 29.2%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 24.2% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年均 24.2%。</p>
</div><p>Runben Biotechnology is experiencing robust revenue growth, forecasted at 24.2% annually, surpassing the CN market average. Despite a high Price-To-Earnings ratio of 42.7x, it remains below the industry average. Earnings are expected to grow significantly at 24.33% per year over the next three years, outpacing market expectations. Recent Q1 results showed strong performance with sales reaching CNY 240.03 million and net income increasing to CNY 44.2 million from last year’s figures.</p>
<div class="lb-trans"><p>潤本股份的收入增長強勁，預計年均增長 24.2%，超過中國市場平均水平。儘管市盈率高達 42.7 倍，但仍低於行業平均水平。預計未來三年盈利將顯著增長，年均增長 24.33%，超出市場預期。最近的第一季度業績顯示強勁表現，銷售額達到 2.4003 億人民幣，淨收入從去年的 4420 萬人民幣增加至 4420 萬人民幣。</p>
</div><ul>
<li>Click here to discover the nuances of Runben Biotechnology with our detailed analytical future growth report.</li>
<li>The analysis detailed in our Runben Biotechnology valuation report hints at an inflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解潤本股份的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們的潤本股份估值報告中的分析暗示其股價相較於估計價值被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/41571584-04fe-437d-8261-8c6c369a4bae/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/41571584-04fe-437d-8261-8c6c369a4bae/chart/ownership-breakdown"/></p>
<p>SHSE:603193 Ownership Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>截至 2025 年 7 月的 SHSE:603193 持股結構</p>
</div><h2>Shanghai Huace Navigation Technology (SZSE:300627)</h2>
<div class="lb-trans"><h2>上海華測導航技術 (SZSE:300627)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Shanghai Huace Navigation Technology Ltd. operates in the field of navigation technology and has a market capitalization of CN¥27.70 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 上海華測導航技術有限公司在導航技術領域運營，市值為 277 億人民幣。</p>
</div><p><strong>Operations:</strong> Shanghai Huace Navigation Technology Ltd. generates revenue from its operations in the navigation technology sector.</p>
<div class="lb-trans"><p><strong>運營：</strong> 上海華測導航技術有限公司的收入來自其導航技術領域的運營。</p>
</div><p><strong>Insider Ownership:</strong> 24.3%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 24.3%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 24.5% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年均 24.5%。</p>
</div><p>Shanghai Huace Navigation Technology is poised for significant growth, with earnings expected to increase by 23.5% annually over the next three years, outpacing the CN market. Revenue is also forecasted to grow at 24.5% per year, surpassing market averages. The company's recent Q1 results showed strong performance with sales rising to CNY 789.12 million and net income reaching CNY 142.74 million from last year’s figures, reflecting robust operational momentum despite a lower-than-industry-average Price-To-Earnings ratio of 44.8x.</p>
<div class="lb-trans"><p>上海華測導航技術有望實現顯著增長，預計未來三年盈利將年均增長 23.5%，超過中國市場。收入也預計年均增長 24.5%，超出市場平均水平。公司最近的第一季度業績顯示強勁表現，銷售額上升至 7.8912 億人民幣，淨收入達到 1.4274 億人民幣，反映出強勁的運營勢頭，儘管市盈率低於行業平均水平，為 44.8 倍。</p>
</div><ul>
<li>Click here and access our complete growth analysis report to understand the dynamics of Shanghai Huace Navigation Technology.</li>
<li>Our expertly prepared valuation report Shanghai Huace Navigation Technology implies its share price may be too high.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整增長分析報告，以瞭解上海華測導航技術的動態。</li>
<li>我們精心準備的上海華測導航技術估值報告暗示其股價可能過高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dfee584a-1911-4802-88a1-e9a681c151fe/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/dfee584a-1911-4802-88a1-e9a681c151fe/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300627 Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>截至 2025 年 7 月的 SZSE:300627 盈利和收入增長</p>
</div><h2>ASE Technology Holding (TWSE:3711)</h2>
<div class="lb-trans"><h2>ASE 科技控股 (TWSE:3711)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> ASE Technology Holding Co., Ltd. and its subsidiaries offer semiconductor manufacturing services, including assembly and testing, across the United States, Taiwan, Europe, Asia, and globally with a market cap of approximately NT$656.25 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ASE 科技控股有限公司及其子公司提供半導體制造服務，包括組裝和測試，覆蓋美國、台灣、歐洲、亞洲及全球，市值約為 6562.5 億新台幣。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include NT$58.94 billion from Testing, NT$276.77 billion from Packaging, and NT$310.28 billion from the Electronic Assembly Segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部門包括測試 58.94 億新台幣、包裝 276.77 億新台幣和電子組裝部門 310.28 億新台幣。</p>
</div><p><strong>Insider Ownership:</strong> 28.5%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 28.5%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 10.9% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 年均 10.9%。</p>
</div><p>ASE Technology Holding shows potential for growth with earnings projected to increase by 24.9% annually over the next three years, outpacing the TW market. Recent revenue figures highlight a positive trend, with Q2 net revenues reaching TWD 150.75 billion compared to TWD 140.24 billion last year. However, its dividend yield of 3.45% is not well covered by free cash flows, and the stock trades significantly below estimated fair value despite low forecasted return on equity at 16.1%.</p>
<div class="lb-trans"><p>ASE 科技控股顯示出增長潛力，預計未來三年盈利將年均增長 24.9%，超過台灣市場。最近的收入數據顯示出積極趨勢，第二季度淨收入達到 1507.5 億新台幣，較去年 1402.4 億新台幣有所增長。然而，其 3.45% 的股息收益率未能很好地覆蓋自由現金流，且股票交易價格顯著低於估計的公允價值，儘管預計的股本回報率較低，僅為 16.1%。</p>
</div><ul>
<li>Take a closer look at ASE Technology Holding's potential here in our earnings growth report.</li>
<li>Our expertly prepared valuation report ASE Technology Holding implies its share price may be lower than expected.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的盈利增長報告中更深入地瞭解 ASE 科技控股的潛力。</li>
<li>我們精心準備的 ASE 科技控股估值報告暗示其股價可能低於預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5e85c188-9c9b-4f8e-8f7f-6f7a9a1226f0/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/5e85c188-9c9b-4f8e-8f7f-6f7a9a1226f0/chart/ownership-breakdown"/></p>
<p>TWSE:3711 Ownership Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>截至 2025 年 7 月的 TWSE:3711 持股結構</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>將想法轉化為行動</h2>
</div><ul>
<li>Gain an insight into the universe of 813 Fast Growing Global Companies With High Insider Ownership by clicking here.</li>
<li>Searching for a Fresh Perspective? AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 813 家快速增長的全球內部持股比例高的公司的宇宙。</li>
<li>尋找新視角？人工智能即將改變醫療保健。這 26 只股票正在從早期診斷到藥物發現等各個方面進行工作。最重要的是——它們的市值都在 100 億美元以下——仍然有機會提前佈局。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖作為財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

值得關注的全球增長型公司：高內部持股公司